scholarly journals Harmony COVID-19: a ready-to-use kit, low-cost detector, and smartphone app for point-of-care SARS-CoV-2 RNA detection

2021 ◽  
Author(s):  
Nuttada Panpradist ◽  
Enos Kline ◽  
Robert G Atkinson ◽  
Michael Roller ◽  
Qin Wang ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Point Of Care ◽  
Low Cost ◽  
High Viral Load ◽  
Respiratory Pathogens ◽  
Rna Detection ◽  
Point Of Care Test ◽  
Viral Transport ◽  
Viral Particles ◽  
First Time

RNA amplification tests sensitively detect SARS-CoV-2 infection, but their complexity and cost are prohibitive for expanding COVID-19 testing. We developed Harmony COVID-19, a point-of-care test using inexpensive consumables, ready-to-use reagents, and a simple device accommodating up to 4 samples simultaneously. Our ready-to-use, 4-plex reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) can detect down to 0.38 SARS-CoV-2 RNA copies/μL and can report in 17 min for high viral load samples (5,000 copies/μL). Harmony detected 97% or 83% of contrived samples with ≥0.5 viral particles/μL in nasal matrix or saliva, respectively. Evaluation in clinical nasal specimens in viral transport media (VTM, n=101) showed 100% detection of RNA extracted from specimens with ≥0.5 SARS-CoV-2 RNA copies/μL, with 100% specificity in specimens positive for other respiratory pathogens. VTM is non-ideal for Harmony system, yet extraction-free analysis of VTM specimens (n=29) had 95% success in specimens with ≥1 RNA copies/μL. Usability testing performed first-time by healthcare workers showed 95% accuracy

scholarly journals Dual electrochemical sensing of spiked virus and SARS-CoV-2 using natural bed-receptor (MV-gal1)

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
E. Ghazizadeh ◽  
Ali Neshastehriz ◽  
Ali Dehghani Firoozabadi ◽  
Mohammad Kaji Yazdi ◽  
Esmail Saievar-Iranizad ◽  
...  
Keyword(s):  
Point Of Care ◽  
Electrochemical Sensing ◽  
Specific Detection ◽  
Early Screening ◽  
Lectin Receptor ◽  
Point Of Care Test ◽  
Viral Particles ◽  
The One ◽  
First Time ◽  
Natural Bed

AbstractIt has been necessary to use methods that can detect the specificity of a virus during virus screening. In this study, we use a dual platform to identify any spiked virus and specific SARS-CoV-2 antigen, sequentially. We introduce a natural bed-receptor surface as Microparticle Vesicle-Galactins1 (MV-gal1) with the ability of glycan binding to screen every spiked virus. MV are the native vesicles which may have the gal-1 receptor. Gal-1 is the one of lectin receptor which can bind to glycan. After dropping the MV-gal1 on the SCPE/GNP, the sensor is turned on due to the increased electrochemical exchange with [Fe(CN)6]−3/−4 probe. Dropping the viral particles of SARS-CoV-2 cause to turn off the sensor with covering the sugar bond (early screening). Then, with the addition of Au/Antibody-SARS-CoV-2 on the MV-gal1@SARS-CoV-2 Antigen, the sensor is turned on again due to the electrochemical amplifier of AuNP (specific detection).For the first time, our sensor has the capacity of screening of any spike virus, and the specific detection of COVID-19 (LOD: 4.57 × 102 copies/mL) by using the natural bed-receptor and a specific antibody in the point of care test.

scholarly journals Design and Adoption of Low-Cost Point-of-Care Diagnostic Devices: Syrian Case

Micromachines ◽  
2021 ◽  
Vol 12 (8) ◽  
pp. 882
Author(s):  
M. Munzer Alseed ◽  
Hamzah Syed ◽  
Mehmet Cengiz Onbasli ◽  
Ali K. Yetisen ◽  
Savas Tasoglu
Keyword(s):  
Civil Wars ◽  
Healthcare Workers ◽  
New Technologies ◽  
Point Of Care ◽  
Low Cost ◽  
Healthcare Services ◽  
Efficient Solutions ◽  
Humanitarian Crises ◽  
Technology Experience ◽  
The Cost

Civil wars produce immense humanitarian crises, causing millions of individuals to seek refuge in other countries. The rate of disease prevalence has inclined among the refugees, increasing the cost of healthcare. Complex medical conditions and high numbers of patients at healthcare centers overwhelm the healthcare system and delay diagnosis and treatment. Point-of-care (PoC) testing can provide efficient solutions to high equipment cost, late diagnosis, and low accessibility of healthcare services. However, the development of PoC devices in developing countries is challenged by several barriers. Such PoC devices may not be adopted due to prejudices about new technologies and the need for special training to use some of these devices. Here, we investigated the concerns of end users regarding PoC devices by surveying healthcare workers and doctors. The tendency to adopt PoC device changes is based on demographic factors such as work sector, education, and technology experience. The most apparent concern about PoC devices was issues regarding low accuracy, according to the surveyed clinicians.

scholarly journals A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

2020 ◽  
Author(s):  
Alain Townsend ◽  
Pramila Rijal ◽  
Julie Xiao ◽  
Tiong Kit Tan ◽  
Kuan-Ying A Huang ◽  
...  
Keyword(s):  
High Performance ◽  
Point Of Care ◽  
Low Cost ◽  
Glycophorin A ◽  
Red Cell ◽  
Special Equipment ◽  
Cell Agglutination ◽  
Haemagglutination Test ◽  
Point Of Care Test ◽  
Laboratory Facilities

ABSTRACTSerological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, detection of seroconversion after vaccination, and for seeking evidence for a level of antibody that may be protective against COVID-19 disease. Several high-performance commercial tests have been described, but these require centralised laboratory facilities that are comparatively expensive, and therefore not available universally. Red cell agglutination tests have a long history in blood typing, and general serology through linkage of reporter molecules to the red cell surface. They do not require special equipment, are read by eye, have short development times, low cost and can be applied as a Point of Care Test (POCT). We describe a red cell agglutination test for the detection of antibodies to the SARS-CoV-2 receptor binding domain (RBD). We show that the Haemagglutination Test (“HAT”) has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR diagnosed infection. The HAT can be titrated, detects rising titres in the first five days of hospital admission, correlates well with a commercial test that detects antibodies to the RBD, and can be applied as a point of care test. The developing reagent is composed of a previously described nanobody to a conserved glycophorin A epitope on red cells, linked to the RBD from SARS-CoV-2. It can be lyophilised for ease of shipping. We have scaled up production of this reagent to one gram, which is sufficient for ten million tests, at a cost of ∼0.27 UK pence per test well. Aliquots of this reagent are ready to be supplied to qualified groups anywhere in the world that need to detect antibodies to SARS-CoV-2, but do not have the facilities for high throughput commercial tests.

scholarly journals AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings

BMC Medicine ◽  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Marina S. Perez-Plazola ◽  
Erika A. Tyburski ◽  
Luke R. Smart ◽  
Thad A. Howard ◽  
Amanda Pfeiffer ◽  
...  
Keyword(s):  
Screening Tool ◽  
Point Of Care ◽  
Low Cost ◽  
Limited Resource ◽  
Absolute Difference ◽  
Severe Anemia ◽  
Detection Range ◽  
Point Of Care Test ◽  
Colour Scale ◽  
Life Saving

Abstract Background Severe anemia is common and frequently fatal for hospitalized patients in limited-resource settings. Lack of access to low-cost, accurate, and rapid diagnosis of anemia impedes the delivery of life-saving care and appropriate use of the limited blood supply. The WHO Haemoglobin Colour Scale (HCS) is a simple low-cost test but frequently inaccurate. AnemoCheck-LRS (limited-resource settings) is a rapid, inexpensive, color-based point-of-care (POC) test optimized to diagnose severe anemia. Methods Deidentified whole blood samples were diluted with plasma to create variable hemoglobin (Hb) concentrations, with most in the severe (≤ 7 g/dL) or profound (≤ 5 g/dL) anemia range. Each sample was tested with AnemoCheck-LRS and WHO HCS independently by three readers and compared to Hb measured by an electronic POC test (HemoCue 201+) and commercial hematology analyzer. Results For 570 evaluations within the limits of detection of AnemoCheck-LRS (Hb ≤ 8 g/dL), the average difference between AnemoCheck-LRS and measured Hb was 0.5 ± 0.4 g/dL. In contrast, the WHO HCS overestimated Hb with an absolute difference of 4.9 ± 1.3 g/dL for samples within its detection range (Hb 4–14 g/dL, n = 405). AnemoCheck-LRS was much more sensitive (92%) for the diagnosis of profound anemia than WHO HCS (22%). Conclusions AnemoCheck-LRS is a rapid, inexpensive, and accurate POC test for anemia. AnemoCheck-LRS is more accurate than WHO HCS for detection of low Hb levels, severe anemia that may require blood transfusion. AnemoCheck-LRS should be tested prospectively in limited-resource settings where severe anemia is common, to determine its utility as a screening tool to identify patients who may require transfusion.

scholarly journals Harmony COVID-19: A ready-to-use kit, low-cost detector, and smartphone app for point-of-care SARS-CoV-2 RNA detection

2021 ◽  
Vol 7 (51) ◽  
Author(s):  
Nuttada Panpradist ◽  
Enos C. Kline ◽  
Robert G. Atkinson ◽  
Michael Roller ◽  
Qin Wang ◽  
...  
Keyword(s):  
Point Of Care ◽  
Low Cost ◽  
Smartphone App ◽  
Rna Detection

Using a biomarker acutely to identify babies at risk of serious adverse effects from antibiotics: where is the ‘Terrible Moral and Medical Dilemma’?

2020 ◽  
pp. medethics-2020-107048
Author(s):  
Anneke M Lucassen ◽  
John Henry McDermott ◽  
William Newman
Keyword(s):  
At Risk ◽  
Adverse Effects ◽  
Point Of Care ◽  
Point Of Care Test ◽  
Pharmacogenetic Test ◽  
Loss Of Hearing ◽  
First Time

We thank Parker and Wright for engaging in this roundtable debate in such a spirited way. The ‘Pharmacogenetic [test] to Avoid Loss of Hearing’ (PALOH) Trial is the first time a genetic point of care test has been applied in the acute neonatal setting; therefore, it is not surprising that questions have been raised which require debate, discussion and clarification. Parker and Wright misattribute several assumptions to the roundtable authors, which we would like to clarify here. Since they raise wider questions about the PALOH trial itself, several of the roundtable discussants have made a joint response.

scholarly journals Host-Modulation Therapy and Chair-Side Diagnostics in the Treatment of Peri-Implantitis

Biosensors ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 44 ◽  
Author(s):  
Timo Sorsa ◽  
Joseph Bacigalupo ◽  
Mauno Könönen ◽  
Pirjo Pärnänen ◽  
Ismo T. Räisänen
Keyword(s):  
Point Of Care ◽  
Low Cost ◽  
Diagnostic Tools ◽  
Low Grade ◽  
Active Matrix ◽  
Point Of Care Test ◽  
Increased Risk ◽  
Prevention And Treatment ◽  
Potential Benefits ◽  
Low Grade Inflammation

Previous studies report periodontitis and peri-implantitis being able to induce systemic low-grade inflammation, which is known to be associated with increased risk for some systemic medical disease such as cardiovascular disease. In this regard, recent studies have shown that host modulation therapy (HMT) together with traditional mechanical and surgical treatment not only cease the progression of periodontitis but also reduce the systemic collagenolytic biomarkers in both oral fluids and circulation. This suggests that the corresponding adjunctive HMT-medication could be effective in the prevention and treatment of dental peri-implantitis, as well. Furthermore, low-cost, safe, and practical oral fluid active matrix metalloproteinase-8 (aMMP-8) lateral-flow immunotests have been proposed as point-of-care/chair-side diagnostic tools to detect peri-implantitis and periodontitis, and to monitor their effective resolutions, while using various therapeutic strategies, including host modulation. This study reports the potential benefits of HMT-medication in the prevention and treatment of dental peri-implantitis among five patients (four of five were current/ex-smokers). In addition, the aMMP-8 point-of-care test diagnosed 20 peri-implantitis and 20 healthy controls correctly. In conclusion, this study and previous studies support the potential effectiveness of HMT-medication(s) and point-of-care/chair-side technologies in the treatment and diagnostics/monitoring of peri-implantitis. However, more studies are needed to further confirm this.

scholarly journals Potential utility of the Genedrive point-of-care test for HCV RNA detection

Gut ◽  
2018 ◽  
Vol 68 (10) ◽  
pp. 1903-1904 ◽  
Author(s):  
Alba Llibre ◽  
Yusuke Shimakawa ◽  
Darragh Duffy
Keyword(s):  
Point Of Care ◽  
Hcv Rna ◽  
Potential Utility ◽  
Rna Detection ◽  
Point Of Care Test

scholarly journals Handyfuge-LAMP: low-cost and electricity-free centrifugation for isothermal SARS-CoV-2 detection in saliva

2020 ◽  
Author(s):  
Ethan Li ◽  
Adam Larson ◽  
Anesta Kothari ◽  
Manu Prakash
Keyword(s):  
Point Of Care ◽  
Low Cost ◽  
Lamp Assay ◽  
Sample Collection ◽  
Rna Detection ◽  
Open Hardware ◽  
Point Of Care Diagnostics ◽  
Simple Protocol ◽  
Specialized Equipment ◽  
The Cost

AbstractPoint of care diagnostics for COVID-19 detection are vital to assess infection quickly and at the source so appropriate measures can be taken. The loop-mediated isothermal amplification (LAMP) assay has proven to be a reliable and simple protocol that can detect small amounts of viral RNA in patient samples (<10 genomes per μL) (Nagamine, Hase, and Notomi 2002). Recently, Rabe and Cepko at Harvard published a sensitive and simple protocol for COVID-19 RNA detection in saliva using an optimized LAMP assay (Rabe and Cepko, 2020).This LAMP protocol has the benefits of being simple, requiring no specialized equipment; rapid, requiring less than an hour from sample collection to readout; and cheap, costing around $1 per reaction using commercial reagents. The pH based colorimetric readout also leaves little ambiguity and is intuitive. However, a shortfall in many nucleic acid-based methods for detection in saliva samples has been the variability in output due to the presence of inhibitory substances in saliva. Centrifugation to separate the reaction inhibitors from inactivated sample was shown to be an effective way to ensure reliable LAMP amplification. However, a centrifuge capable of safely achieving the necessary speeds of 2000 RPM for several minutes often costs hundreds of dollars and requires a power supply.We present here an open hardware solution- Handyfuge - that can be assembled with readily available components for the cost of <5 dollars a unit and could be used together with the LAMP assay for point of care detection of COVID-19 RNA from saliva. The device is then validated using the LAMP protocol from Rabe and Cepko. With the use of insulated coolers for reagent supply chain and delivery, the assay presented can be completed without the need for electricity or any laboratory scale infrastructure.

Sign in / Sign up

Export Citation Format

Share Document